Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions
Authors:
Top Cited Papers
- 10 April 2024
- journal article
- review article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (8) , 5963-5998
Abstract
As a tripartite cell death switch, B-cell lymphoma protein 2 (Bcl-2) family members precisely regulate the endogenous apoptosis pathway in response to various cell signal stresses through protein-protein interactions. Myeloid leukemia-1 (Mcl-1), a key anti-apoptotic Bcl-2 family member, is positioned downstream in the endogenous apoptotic pathway and plays a central role in regulating mitochondrial function. Mcl-1 is highly expressed in a variety of hematological malignancies and solid tumors, contributing to tumorigenesis, poor prognosis, and chemoresistance, making it an attractive target for cancer treatment. This Perspective aims to discuss the mechanism by which Mcl-1 regulates apoptosis and non-apoptotic functions in cancer cells and to outline the discovery and optimization process of potent Mcl-1 modulators. In addition, we summarize the structural characteristics of potent inhibitors that bind to Mcl-1 through multiple co-crystal structures and analyze the cardiotoxicity caused by current Mcl-1 inhibitors, providing prospects for rational targeting of Mcl-1.Keywords
Funding Information
- Liaoning Revitalization Talents Program (XLYC1902089)
- Shenyang Pharmaceutical University (YQ202304)
- National Natural Science Foundation of China (82173687)
This publication has 158 references indexed in Scilit:
- BCL-2 protein family: attractive targets for cancer therapyApoptosis, 2022
- Mutation in MCL1 predicted loop to helix structural transition stabilizes MCL1–Bax binding interaction favoring cancer cell survivalProteins: Structure, Function, and Bioinformatics, 2022
- Drimane Derivatives as the First Examples of Covalent BH3 Mimetics that Target MCL‐1ChemMedChem, 2021
- Loss of MCL1 function sensitizes the MDA‐MB‐231 breast cancer cells to rh‐TRAIL by increasing DR4 levelsJournal of Cellular Physiology, 2019
- Affinity Enhancement of Protein Ligands by Reversible Covalent Modification of Neighboring Lysine ResiduesAngewandte Chemie International Edition, 2018
- Experimental Characterization of the Binding Affinities between Proapoptotic BH3 Peptides and Antiapoptotic Bcl‐2 ProteinsChemMedChem, 2018
- Lysine‐Targeting Covalent InhibitorsAngewandte Chemie International Edition, 2017
- Fragment‐Based Design, Synthesis, and Biological Evaluation of 1‐Substituted‐indole‐2‐carboxylic Acids as Selective Mcl‐1 InhibitorsArchiv der Pharmazie, 2016
- Deactivation of Mcl‐1 by Dual‐Function Small‐Molecule Inhibitors Targeting the Bcl‐2 Homology 3 Domain and Facilitating Mcl‐1 UbiquitinationAngewandte Chemie International Edition, 2016
- Structure‐Based Design of Inhibitors of Protein–Protein Interactions: Mimicking Peptide Binding EpitopesAngewandte Chemie International Edition, 2015